Charles S. Dai

1.4k total citations
25 papers, 633 citations indexed

About

Charles S. Dai is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Oncology. According to data from OpenAlex, Charles S. Dai has authored 25 papers receiving a total of 633 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pulmonary and Respiratory Medicine, 18 papers in Cancer Research and 10 papers in Oncology. Recurrent topics in Charles S. Dai's work include Cancer Genomics and Diagnostics (14 papers), Prostate Cancer Treatment and Research (8 papers) and Advanced Breast Cancer Therapies (5 papers). Charles S. Dai is often cited by papers focused on Cancer Genomics and Diagnostics (14 papers), Prostate Cancer Treatment and Research (8 papers) and Advanced Breast Cancer Therapies (5 papers). Charles S. Dai collaborates with scholars based in United States, Italy and Ukraine. Charles S. Dai's co-authors include Nima Sharifi, Hannelore V. Heemers, Scott M. Dehm, Leif W. Ellisen, Andrew J. Stephenson, Jianneng Li, Eric A. Klein, Ziqi Zhu, Clifford C. Sung and Raya Khanin and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Cell and Cancer Research.

In The Last Decade

Charles S. Dai

24 papers receiving 629 citations

Peers

Charles S. Dai

PRM

ONCOL

EDM

Ahmed Basudan Saudi Arabia

Elisavet Paplomata United States

Gabriel Olmedilla Spain

Ailin Shan United States

Lang Li China

Thomas Spires United States

Yu Gan China

Xinan Wang China

Kathy E. Wiley United States

F. K. Habib United Kingdom

Ahmed Basudan Saudi Arabia

Charles S. Dai

238 ×0.6

PRM

238 ×1.0

189 ×1.1

289 ×1.9

ONCOL

39 ×0.4

EDM

Citations per year, relative to Charles S. Dai Charles S. Dai (= 1×) peers Ahmed Basudan

Countries citing papers authored by Charles S. Dai

Since Specialization

Citations

This map shows the geographic impact of Charles S. Dai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles S. Dai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles S. Dai more than expected).

Fields of papers citing papers by Charles S. Dai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charles S. Dai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles S. Dai. The network helps show where Charles S. Dai may publish in the future.

Co-authorship network of co-authors of Charles S. Dai

This figure shows the co-authorship network connecting the top 25 collaborators of Charles S. Dai. A scholar is included among the top collaborators of Charles S. Dai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charles S. Dai. Charles S. Dai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dai, Charles S., Avanish Mishra, Jon Edd, et al.. (2025). Circulating tumor cells: Blood-based detection, molecular biology, and clinical applications. Cancer Cell. 43(8). 1399–1422. 3 indexed citations

Medford, Arielle J., Yuval Gefen, Andrzej Niemierko, et al.. (2025). Genomic and proteomic profiling of GATA3 mutant metastatic hormone receptor-positive breast cancer and impact on clinical outcomes. Breast Cancer Research and Treatment. 212(3). 437–447.

Gerratana, Lorenzo, Andrew A. Davis, Carolina Reduzzi, et al.. (2024). Integrating machine learning-predicted circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in metastatic breast cancer: A proof of principle study on endocrine resistance profiling. Cancer Letters. 609. 217325–217325. 13 indexed citations

Gerratana, Lorenzo, Andrew A. Davis, Carolina Reduzzi, et al.. (2023). Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker Analysis. JCO Precision Oncology. 7(7). e2200531–e2200531. 7 indexed citations

Medford, Arielle J., Lauren Oshry, Bariş Boyraz, et al.. (2023). TRK inhibitor in a patient with metastatic triple-negative breast cancer and NTRK fusions identified via cell-free DNA analysis. Therapeutic Advances in Medical Oncology. 15. 2597580–2597580. 5 indexed citations

Gerratana, Lorenzo, Katherine Clifton, Arielle J. Medford, et al.. (2023). Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer. Clinical Cancer Research. 29(16). 3092–3100. 4 indexed citations

Medford, Arielle J., Ignaty Leshchiner, Lesli A. Kiedrowski, et al.. (2023). ESR1 mutational landscape and impact of co-existing resistance variants on clinical outcomes in patients with metastatic breast cancer.. Journal of Clinical Oncology. 41(16_suppl). 1074–1074. 1 indexed citations

Dai, Charles S. & Leif W. Ellisen. (2023). Revisiting Androgen Receptor Signaling in Breast Cancer. The Oncologist. 28(5). 383–391. 18 indexed citations

Gerratana, Lorenzo, Andrew A. Davis, Katherine Clifton, et al.. (2023). Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysis. Breast Cancer Research. 25(1). 112–112. 7 indexed citations

10.

Dai, Charles S., Scott M. Dehm, & Nima Sharifi. (2023). Targeting the Androgen Signaling Axis in Prostate Cancer. Journal of Clinical Oncology. 41(26). 4267–4278. 78 indexed citations

11.

Gerratana, Lorenzo, Katherine Clifton, Ami N. Shah, et al.. (2022). Abstract P2-01-01: Genetic alterations detected by circulating tumor DNA (ctDNA) in HER2-low metastatic breast cancer (MBC). Cancer Research. 82(4_Supplement). P2–1. 1 indexed citations

12.

Gerratana, Lorenzo, Andrew A. Davis, Charles S. Dai, et al.. (2021). Landscape of GATA3 mutations identified from circulating tumor DNA clinical testing and their impact on disease outcomes in estrogen receptor-positive (ER+) metastatic breast cancers treated with endocrine therapies.. Journal of Clinical Oncology. 39(15_suppl). 1065–1065. 4 indexed citations

13.

Dai, Charles S., Vishnu Ganesan, Yaw A. Nyame, et al.. (2019). Older Age at Diagnosis and Initial Disease Volume Predict Grade Reclassification Risk on Confirmatory Biopsy in Patients Considered for Active Surveillance. Urology. 130. 106–112. 4 indexed citations

14.

Nyame, Yaw A., Lamont Wilkins, Daniel Greene, et al.. (2019). Assessing the relationship between statin use and oncologic outcomes among men electing active surveillance for localized prostate cancer. Prostate Cancer and Prostatic Diseases. 22(4). 617–623. 2 indexed citations

15.

Gao, Xiaomei, Charles S. Dai, Shengsong Huang, et al.. (2018). Functional Silencing of HSD17B2 in Prostate Cancer Promotes Disease Progression. Clinical Cancer Research. 25(4). 1291–1301. 41 indexed citations

16.

Dai, Charles S., Yoon-Mi Chung, Evan Kovac, et al.. (2017). Direct Metabolic Interrogation of Dihydrotestosterone Biosynthesis from Adrenal Precursors in Primary Prostatectomy Tissues. Clinical Cancer Research. 23(20). 6351–6362. 38 indexed citations

17.

Ganesan, Vishnu, Charles S. Dai, Yaw A. Nyame, et al.. (2017). Prognostic Significance of a Negative Confirmatory Biopsy on Reclassification Among Men on Active Surveillance. Urology. 107. 184–189. 8 indexed citations

18.

Dai, Charles S., Hannelore V. Heemers, & Nima Sharifi. (2017). Androgen Signaling in Prostate Cancer. Cold Spring Harbor Perspectives in Medicine. 7(9). a030452–a030452. 299 indexed citations

19.

Nyame, Yaw A., Nima Almassi, Samuel Haywood, et al.. (2017). Intermediate-Term Outcomes for Men with Very Low/Low and Intermediate/High Risk Prostate Cancer Managed by Active Surveillance. The Journal of Urology. 198(3). 591–599. 32 indexed citations

20.

Danila, Daniel C., Aseem Anand, Nikolaus Schultz, et al.. (2013). Analytic and Clinical Validation of a Prostate Cancer–Enhanced Messenger RNA Detection Assay in Whole Blood as a Prognostic Biomarker for Survival. European Urology. 65(6). 1191–1197. 60 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact